AKT1 and breast carcinoma: In conclusion, we synthesized trisubstituted imidazoles, identified the bioactive cytotoxic lead structure, predicted the likely target and demonstrated in vitro efficacy of lead compound to abrogate the activation of the PI3K/Akt/mTOR pathway in human breast cancer cells.